Clinical trials

4

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

LIQUIBAND FIX8® for Ventral Incisional Hernia

This study is designed to evaluate the safety and performance of device LiquiBand FIX8 Open hernia mesh fixation device. The use of this device is not experimental, as it is already approved for use in the EU (CE-marked). This is a retrospective post market clinical follow-up study to collect information about the use of the device in a real-world setting for ventral incisional hernia repair. Ventral incisional hernias occur following surgery and the most common method of treatment includes implanting a mesh, which in the case of ventral incisional hernia, the standard of care is intra-peritoneal onlay mesh. This is fixed in place using sutures, tacks or adhesive. The LiquiBand FIX8 Open device is an atraumatic device specifically engineered for strong mesh fixation of hernia repair meshes. Hernia repair meshes are woven sheets of flexible synthetic plastic which are placed tension-free over the weakness in the peritoneum abdominal wall, essentially 'plugging' it up. Tension is created in the abdominal wall during repair, but the mesh allows this tension to be spread out. The mesh must be secured to the underlying tissue and this is often done with the use of tacks or sutures, however, the study device instead uses a glue (N-Butyl 2 cyanoacrylate adhesive) to secure the mesh. The FIX8 Open device is designed for the application of this glue to the implanted hernia repair mesh in order to fix the mesh to the underlying tissue. When the glue is applied to the mesh and tissue, it polymerises (forms a chemical bond) due to the moisture on the tissue surface within approximately 10 seconds and allows the mesh to remain in the correct position. The study device can also be used to close topical wounds (the opening that the surgeon makes on the surface to access the hernia).

Participants needed: 148
Trial details
Age: 18-80Biological sex: AllType: ObservationalSponsor: Advanced Medical Solutions Ltd.Updated: Dec 19, 2025Locations: 1
Eligibility criteria

Patient is ≥ 18 years of age and ≤ 80 years of age. [+3]

Every patient who required a ventral incisional hernia repair without concomitan...

Status: Recruiting

PMCF Study of Debridement Pad

The design of the study is a clinical trial of Debridement Pad in subjects with superficial, chronic and acute wounds consisting of Diabetic ulcers, Arterial and Venous Leg ulcers, Pressure ulcers, Postoperative wounds healing by secondary intention, traumatic or surgical wounds and burns and scalds. The performance data from this study will support clinically meaningful rates of successful improvement in wound bed condition immediately after treatment.

Participants needed: 184
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Advanced Medical Solutions Ltd.Updated: Dec 1, 2025Locations: 1
Eligibility criteria

Males or females aged 18 years or above. [+6]

Patients who are known to be non-compliant with medical treatment [+6]

Status: Not yet recruiting

Seal-G/ Seal-G MIST Long-Term Follow-up PMCF (Continue) Study

Postoperative complications following colon anastomosis surgery, such as adhesions, stenosis, stricture and obstruction, can significantly impact patient outcomes. The use of surgical sealants has been proposed as a means to mitigate anastomotic complications by providing a protective barrier over the anastomosis site, reducing the risk or the severity of anastomotic leak. The previous post-market clinical follow-up (PMCF) study assessed the short-term safety and performance of SEAL-G surgical sealants in preventing anastomotic leaks and early post-operative complications. However, long-term data are needed to establish its sustained safety and effectiveness. This continuation study aims to evaluate the long-term impact of the SEAL-G/MIST surgical sealant on post-operative complications over 12+ months after surgery. The study will compare complication rates in patients treated with the surgical sealant to a retrospective comparable control group who underwent similar procedures without the sealant.

Participants needed: 208
Trial details
Age: 18-85Biological sex: AllType: ObservationalSponsor: Advanced Medical Solutions Ltd.Updated: Aug 3, 2025
Eligibility criteria

Treatment Group: Patients participated and completed all visits in the previous... [+1]

Patients with missing or incomplete medical records that prevent retrospective c... [+2]

Status: Not yet recruiting

In'Oss™ (MBCP® Putty) Ortho

Study of the osteoconductive potential of the injectable bone substitute In'Oss™ (MBCP® Putty) in the filling of orthopaedic bone defects to collect Post-Market Clinical Follow-up (PMCF) data for the CE-marked In'Oss™ (MBCP® Putty) device in the orthopaedic trauma surgery

Participants needed: 100
Trial details
Age: 18-85Biological sex: AllType: ObservationalSponsor: Advanced Medical Solutions Ltd.Updated: Feb 5, 2025
Eligibility criteria

Patient is male or female, 18 - 85 years old; [+5]

Patient has had an infection in the same extremity within last 24 months; [+16]